Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies

References

• World Health Organization. 2023a. WHO coronavirus (COVID-19) dashboard [accessed 2024 Jan 10]. Available from: https://data.who.int/dashboards/covid19/cases.
   Google Scholar
• Ge Y, Martinez L, Sun S, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19: a population-based cohort study in Zhejiang Province, China. JAMA Intern Med. 2021;181(10):1343–1350. doi: 10.1001/jamainternmed.2021.4686
   PubMed Web of Science ®Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302. doi: 10.1016/S1473-3099(22)00320-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2023c. Tracking SARS-CoV-2 variants [accessed 2023 Aug 11]. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
   Google Scholar
• Volz E, Hill V, McCrone JT, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64–75.e11. doi: 10.1016/j.cell.2020.11.020
   PubMed Web of Science ®Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162–177. doi: 10.1038/s41579-022-00841-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2023d. Statement on the update of WHO’s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest [accessed 2023 Aug 12]. Available from: https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest.
   Google Scholar
• Singh DD, Parveen A, Yadav DK. SARS-CoV-2: emergence of new variants and effectiveness of vaccines. Front Cell Infect Microbiol. 2021;11:777212. doi: 10.3389/fcimb.2021.777212
   PubMed Web of Science ®Google Scholar
• Buchan S, Chung H, Brown K, et al. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5(9):e2232760. doi: 10.1001/jamanetworkopen.2022.32760
   PubMed Web of Science ®Google Scholar
• Rzymski P, Pokorska-Śpiewak M, Jackowska T, et al. Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review. Vaccines. 2023;11(9):1502. doi: 10.3390/vaccines11091502
   Web of Science ®Google Scholar
• Gong W, Parkkila S, Wu X, et al. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Int Rev Immunol. 2023;42(6):393–414. doi: 10.1080/08830185.2022.2079642
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Guidance. 2022. COVID-19: epidemiology, virology and clinical features [accessed 2023 Aug 6]. Available from: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-background-information/wuhan-novel-coronavirus-epidemiology-virology-and-clinical-features.
   Google Scholar
• World Health Organization. 2023b. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic [accessed 2023 Aug 7]. Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.
   Google Scholar
• Nature Editorial. This is no time to stop tracking COVID-19. Nature. 2022;603(7902):550. doi: 10.1038/d41586-022-00788-y
   PubMed Web of Science ®Google Scholar
• Gov.UK. Press release. COVID-19 testing approach from April; 2023 [accessed 2023 Aug 5] Available from: https://www.gov.uk/government/news/covid-19-testing-approach-from-april-2023.
   Google Scholar
• Contreras S, Iftekhar EN, Priesemann V. From emergency response to long-term management: the many faces of the endemic state of COVID-19. Lancet Reg Health Eur. 2023;30:100664.
   PubMedGoogle Scholar
• Phillips S 2023. The COVID-19 pandemic will be over when Americans think it is [accessed 2023 Aug 3]. Available from: https://time.com/6251077/covid-19-pandemic-end/.
   Google Scholar
• Charumilind S, Craven M, Lamb J, et al. 2022. When will the COVID-19 pandemic end? [accessed 2023 Sep 4]. Available from: https://www.mckinsey.com/industries/healthcare/our-insights/when-will-the-covid-19-pandemic-end.
   Google Scholar
• Pascall DJ, Vink E, Blacow R, et al. Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. J Infect. 2023;87:128–135. doi: 10.1016/j.jinf.2023.05.019
   PubMed Web of Science ®Google Scholar
• Callaway E. COVID’s future: mini-waves rather than seasonal surges. Nature. 2023;617(7960):229–230. doi: 10.1038/d41586-023-01437-8
   PubMed Web of Science ®Google Scholar
• Munteanu V, Saldana M, Ciorba D, et al. 2024. SARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities [accessed 2023 Mar 13]. Available from: https://arxiv.org/abs/2309.13326.
   Google Scholar
• University of California MERCED. Summary of global SARS-CoV-2 wastewater monitoring efforts by UC Merced Researchers. 2024 [accessed 2024 Mar 7]. Available from: https://www.arcgis.com/apps/dashboards/c778145ea5bb4daeb58d31afee389082.
   Google Scholar
• ESR Wastewater Surveillance. 2024. Week ending 3 Mar 2024 [accessed 2024 Mar 7]. Available from: https://esr-cri.shinyapps.io/wastewater/.
   Google Scholar
• Koelle K, Martin MA, Antia R, et al. The changing epidemiology of SARS-CoV-2. Science. 2022;375(6585):1116–1121. doi: 10.1126/science.abm4915
   PubMed Web of Science ®Google Scholar
• Phillips N. The coronavirus is here to stay - here’s what that means. Nature. 2021;590(7846):382–384. doi: 10.1038/d41586-021-00396-2
   PubMed Web of Science ®Google Scholar
• Hyams C, Challen R, Marlow R, et al. Severity of omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556. doi: 10.1016/j.lanepe.2022.100556
   PubMedGoogle Scholar
• Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437–446. doi: 10.1016/S0140-6736(22)00017-4
   PubMed Web of Science ®Google Scholar
• Nealon J, Cowling BJ. Omicron severity: milder but not mild. Lancet. 2022;399(10323):412–413. doi: 10.1016/S0140-6736(22)00056-3
   PubMed Web of Science ®Google Scholar
• Flahault A, Calmy A, Costagliola D, et al. No time for complacency on COVID-19 in Europe. Lancet. 2023;401(10392):1909–1912. doi: 10.1016/S0140-6736(23)01012-7
   PubMed Web of Science ®Google Scholar
• Fernandes Q, Inchakalody VP, Merhi M, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524–540. doi: 10.1080/07853890.2022.2031274
   PubMed Web of Science ®Google Scholar
• Triveri A, Serapian SA, Marchetti F, et al. SARS-CoV-2 spike protein mutations and escape from antibodies: a computational model of epitope loss in variants of concern. J Chem Inf Model. 2021;61(9):4687–4700. doi: 10.1021/acs.jcim.1c00857
   PubMed Web of Science ®Google Scholar
• Otto S, Day T, Arino J, et al. The origins and potential future of SARS-CoV-2 variants ofconcern in the evolving COVID-19 pandemic. Curr Biol. 2021;31(14):R918–R929. doi: 10.1016/j.cub.2021.06.049
   PubMed Web of Science ®Google Scholar
• Liu J, Xie W, Wang Y, et al. A comparative overview of COVID-19, MERS and SARS: review article. Int J Surg. 2020;81:1–8. doi: 10.1016/j.ijsu.2020.07.032
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2023. Updated COVID-19 vaccines for use in the United States beginning in Fall 2023 [accessed 2023 Sep 2]. Available from: https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023.
   Google Scholar
• European Medicines Agency. 2023a. ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants [accessed 2023 Sep 2]. Available from: https://www.ema.europa.eu/en/news/ema-ecdc-statement-updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants.
   Google Scholar
• U.S. Food and Drug Administration. 2023d. FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants [accessed 2023 Nov 20]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating.
   Google Scholar
• Nortate KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalmedicine. 2022 Nov;53:101624. doi: 10.1016/j.eclinm.2022.101624
   PubMedGoogle Scholar
• Chen J, Zhou T, Zhang Y, et al. The reservoir of latent HIV. Front Cell Infect Microbiol. 2022;12:945956. doi: 10.3389/fcimb.2022.945956
   PubMed Web of Science ®Google Scholar
• HIV.gov. 2023. The Global HIV and AIDS Epidemic [accessed 2023 Sep 1]. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics/.
   Google Scholar
• Pasternak AO, Berkhout B. HIV persistence: silence or resistance? Curr Opin Virol. 2023;59:101301. doi: 10.1016/j.coviro.2023.101301
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2022e. Global tuberculosis report [accessed 2023 Aug 8]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
   Google Scholar
• World Health Organization. 2022. World malaria report [accessed 2024 Mar 13]. Available from: https://www.who.int/publications/i/item/9789240064898.
   Google Scholar
• World Health Organization. 2023. Fact sheet: dengue and severe dengue [accessed 2024 Mar 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
   Google Scholar
• Dong R, Hu T, Zhang Y, et al. Assessing the transmissibility of the new SARS-CoV-2 variants: from Delta to Omicron. Vaccines (Basel). 2022;10(4):496. doi: 10.3390/vaccines10040496
   PubMed Web of Science ®Google Scholar
• Arabi M, Al-Najjar Y, Mhaimeed N, et al. Severity of the omicron SARS-CoV-2 variant compared with the previous lineages: a systematic review. J Cell Mol Med. 2023;27(11):1443–1464. doi: 10.1111/jcmm.17747
   PubMed Web of Science ®Google Scholar
• Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706–714. doi: 10.1038/s41586-022-04474-x
   PubMed Web of Science ®Google Scholar
• Xia S, Wang L, Jiao F, et al. SARS-CoV-2 omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors. Emerg Microbes Infect. 2023;12(1):2178241. doi: 10.1080/22221751.2023.2178241
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Dobrowolska K, et al. Change in the clinical picture of hospitalized patients with COVID-19 between the early and late period of dominance of the Omicron SARS-CoV-2 variant. J Clin Med. 2023;12(17):5572. doi: 10.3390/jcm12175572
   PubMed Web of Science ®Google Scholar
• Al Hasan SM, Saulam J, Mikami F, et al. COVID-19 outbreak trends in South Africa: a comparison of omicron (B.1.1.529), Delta (B.1.617.2), and beta (B.1.351) variants outbreak periods. J Infect Public Health. 2022;15(7):726–733. doi: 10.1016/j.jiph.2022.05.011
   PubMed Web of Science ®Google Scholar
• Miller NL, Clark T, Raman R, et al. An antigenic space framework for understanding antibody escape of SARS-CoV-2 variants. Viruses. 2021;13(10):2009. doi: 10.3390/v13102009
   PubMed Web of Science ®Google Scholar
• Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 2023;614(7948):521–529. doi: 10.1038/s41586-022-05644-7
   PubMed Web of Science ®Google Scholar
• Bouhaddou M, Reuschl AK, Polacco BJ, et al. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell. 2023;186(21):4597–4614.e26.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen J, Wei GW. Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America. J Phys Chem Lett. 2021;12(49):11850–11857. doi: 10.1021/acs.jpclett.1c03380
   PubMed Web of Science ®Google Scholar
• Ito J, Suzuki R, Uriu K, et al. Convergent evolution of SARS-CoV-2 omicron subvariants leading to the emergence of BQ.1.1 variant. Nat Commun. 2023;14(1):2671. doi: 10.1038/s41467-023-38188-z
   PubMed Web of Science ®Google Scholar
• Chen J, Gao K, Wang R, et al. Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. J Chem Sci. 2021;12(20):6929–6948. doi: 10.1039/d1sc01203g
   Google Scholar
• Chakraborty C, Bhattacharya M, Sharma AR, et al. A comprehensive analysis of the mutational landscape of the newly emerging omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs. Geroscience. 2022;44(5):2393–2425. doi: 10.1007/s11357-022-00631-2
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St. Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9. doi: 10.1016/j.cell.2021.03.013
   PubMed Web of Science ®Google Scholar
• Liu Q, Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132. doi: 10.1186/s40249-021-00915-3
   PubMed Web of Science ®Google Scholar
• Looi MK, Mahase E. Has COVID-19 become milder? BMJ. 2022 Oct 27;379:o2516. doi: 10.1136/bmj.o2516
   PubMedGoogle Scholar
• Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet. 2022;399(10335):1618–1624. doi: 10.1016/S0140-6736(22)00327-0
   PubMed Web of Science ®Google Scholar
• El-Sadr W, Vasan A, El-Mohandes A. Facing the new covid-19 reality. N Engl J Med. 2023;388(5):385–387. doi: 10.1056/NEJMp2213920
   PubMed Web of Science ®Google Scholar
• CNN Health. 2022. Press release. Demand for covid-19 testing is falling, but experts caution it’s as important as ever [accessed 2024 Mar 1]. Available from: https://edition.cnn.com/2022/03/01/health/covid-testing-demand-decline/index.html.
   Google Scholar
• Martins-Filho PR, de Oliveira Júnior Jerocílio Maciel, dos Santos Cliomar Alves. Case-fatality rates and risk of death from COVID-19 and influenza A/H3N2 in Brazil: a nationwide ecological study. Enferm Infec Microbiol Clin. 2023;41(3):199–201. doi: 10.1016/j.eimc.2022.05.015
   PubMed Web of Science ®Google Scholar
• Xie Y, Choi T, Al-Aly Z. Risk of death in patients hospitalized for COVID-19 vs seasonal influenza in Fall-Winter 2022–2023. JAMA. 2023;329(19):e235348. doi: 10.1001/jama.2023.5348
   Web of Science ®Google Scholar
• Fancourt D, Bu F, Wan Mak H, et al. 2022. Wellcome trust & Nuffield Foundation. UCL COVID-19 social study report (week 105) [accessed 2023 Sep 2]. Available from: https://www.covidsocialstudy.org/results.
   Google Scholar
• Cuevas Barron G, Laryea-Adjei G, Vike-Freiberga V, et al. Safeguarding people living in vulnerable conditions in the COVID-19 era through universal health coverage and social protection. Lancet Public Health. 2022;7(1):e86–92. doi: 10.1016/S2468-2667(21)00235-8
   PubMed Web of Science ®Google Scholar
• Paremoer L, Nandi S, Serag H, et al. Covid-19 pandemic and the social determinants of health. BMJ. 2021;372:n129. doi: 10.1136/bmj.n129
   PubMed Web of Science ®Google Scholar
• ONS. Coronavirus (COVID-19) latest insights [accessed 2023 Aug 4]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights.
   Google Scholar
• IFS. 2022. Long COVID and the labour market [accessed 2023 Aug 2]. Available from: https://ifs.org.uk/sites/default/files/output_url_files/BN346-Long-COVID-and-the-labour-market.pdf.
   Google Scholar
• Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417. doi: 10.1001/jamanetworkopen.2021.11417
   PubMed Web of Science ®Google Scholar
• ECDPC. 2022. Risk of severe pressure on healthcare systems due to RSV, flu and COVID-19 co-circulation [accessed 2023 Aug 2]. Available from: https://www.ecdc.europa.eu/en/news-events/risk-severe-pressure-healthcare-systems-due-rsv-flu-and-covid-19-co-circulation.
   Google Scholar
• Hoffman M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11. doi: 10.1016/j.cell.2021.12.032
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2023b. Coronavirus (COVID-19) update: FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines [accessed 2023 Nov 12]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines.
   Google Scholar
• U.S. Food and Drug Administration. 2023c. COVID-19 vaccines for 2023-2024 [accessed 2023 Dec 12]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2023-2024.
   Google Scholar
• Evans JP, Liu S-L. Challenges and prospects in developing future SARS-CoV-2 vaccines: overcoming original antigenic sin and inducing broadly neutralizing antibodies. J Immunol. 2023;211:1459–1467. doi: 10.4049/jimmunol.2300315
   PubMed Web of Science ®Google Scholar
• Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023;29(2):344–347. doi: 10.1038/s41591-022-02162-x
   PubMed Web of Science ®Google Scholar
• Abbasi J. What to know about EG.5, the latest SARS-CoV-2 “variant of interest”. JAMA. 2023;330(10):900–901. doi: 10.1001/jama.2023.16498
   PubMed Web of Science ®Google Scholar
• Fang L, Xu J, Zhao Y, et al. The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2. Front Microbiol. 2023;14:1228128. doi: 10.3389/fmicb.2023.1228128
   PubMed Web of Science ®Google Scholar
• Ma KC, Shirk P, Lambrou AS, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of omicron lineages — United States, January 2022–May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(24):651–656. doi: 10.15585/mmwr.mm7224a2
   PubMed Web of Science ®Google Scholar
• ECDPC. 2023. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA [accessed 2023 Sep 20]. Available from: https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans.
   Google Scholar
• World Health Organization. 2023f. SAGE updates COVID-19 vaccination guidance [accessed 2023 Sep 12]. Available from: https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance.
   Google Scholar
• European Medicines Agency. 2023b. COVID-19 vaccines: key facts [accessed 2023 Sep 20]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-key-facts.
   Google Scholar
• Kuitunen I, Artama M, Mäkelä L, et al. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect Dis J. 2020;39(12):e423–e427. doi: 10.1097/INF.0000000000002845
   PubMed Web of Science ®Google Scholar
• European Commission. 2022. Joint statement by Commissioner Stella Kyriakides, WHO regional Director for Europe Dr Hans Henri P. Kluge and Director of the ECDC Dr Andrea Ammon: working together towards COVID-19 and seasonal influenza vaccinations for this winter [accessed 2023 Sep 4]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/statement_22_6117.
   Google Scholar
• World Health Organization. 2023g. Considerations for integrating COVID-19 vaccination into immunization programmes and primary health care for 2022 and beyond [accessed 2023 Jul 3]. Available from: https://www.who.int/publications/i/item/9789240064454.
   Google Scholar
• World Health Organization. 2023h. Guidance on developing national COVID-19 vaccination policy and integrating COVID-19 vaccination into national immunization programmes and broader health care delivery mechanisms in the WHO European Region: August 2023 [accessed 2023 Nov 20]. Available from: https://www.who.int/europe/publications/i/item/WHO-EURO-2023-7892-47660-70230.
   Google Scholar
• Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(2):167–179. doi: 10.1016/S2213-2600(21)00409-4
   PubMed Web of Science ®Google Scholar
• Dulfer EA, Geckin B, Taks EJM, et al. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial. Lancet Reg Health Eur. 2023;29:100628. doi: 10.1016/j.lanepe.2023.100628
   PubMedGoogle Scholar
• Cadeddu C, Castagna C, Sapienza M, et al. Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review. Hum Vaccin Immunother. 2021;17(11):4470–4486. doi: 10.1080/21645515.2021.1961466
   PubMed Web of Science ®Google Scholar
• Giambi C, Fabiani M, D’Ancona F, et al. Parental vaccine hesitancy in Italy – results from a national survey. Vaccine. 2018;36(6):779–787. doi: 10.1016/j.vaccine.2017.12.074
   PubMed Web of Science ®Google Scholar
• Ecker F, Kutalek R. ‘I’m not an anti-vaxer!’–vaccine hesitancy among physicians: a qualitative study. Eur J Public Health. 2021;31(6):1157–1163. doi: 10.1093/eurpub/ckab174
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Britton A, Fleming-Dutra KE. Building the U.S. COVID-19 vaccine effectiveness program: past successes and future directions. Vaccine. 2023;S0264–410X(23)01435–4. doi: 10.1016/j.vaccine.2023.12.002
   Google Scholar
• Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. Front Public Health. 2023;10:1087138. doi: 10.3389/fpubh.2022.1087138
   PubMed Web of Science ®Google Scholar
• Batista C, Hotez P, Amor YB, et al. The silent and dangerous inequity around access to COVID-19 testing: a call to action. EClinicalMedicine. 2022;43:101230. doi: 10.1016/j.eclinm.2021.101230
   PubMedGoogle Scholar
• Sheriden C. COVID-19 vaccine makers chase variant-ready vaccines. Nat Biotechnol. 2022;40(2):141–143. doi: 10.1038/d41587-022-00001-5
   PubMed Web of Science ®Google Scholar
• Cohen JA, Stuart RM, Panovska-Griffiths J, et al. The changing health impact of vaccines in the COVID-19 pandemic: a modeling study. Cell Rep. 2023;42(4):112308. doi: 10.1016/j.celrep.2023.112308
   PubMed Web of Science ®Google Scholar
• Qu P, Xu K, Faraone JN, et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Cell. 2024;187(3):585–595.e6. doi: 10.1016/j.cell.2023.12.026
   PubMed Web of Science ®Google Scholar
• Zhang L, Kempf A, Nehlmeier I, et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell. 2024;187(3):596–608.e17. doi: 10.1016/j.cell.2023.12.025
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Sakamoto A, Ozuru R, et al. The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines. Int J Infect Dis. 2024;139:1–5. doi: 10.1016/j.ijid.2023.11.028
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo Y, Tam AR, et al. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. bioRxiv. 2023; May 4. doi: 10.1101/2023.05.03.539268
   Google Scholar
• Yisimayi A, Song W, Wang J, et al. Repeated omicron infection alleviates SARS-CoV-2 immune imprinting. bioRxiv. 2023; May 3. doi: 10.1101/2023.05.01.538516.
   Google Scholar
• Marks P, Gruppuso PA, Adashi EY. Urgent need for next-generation COVID-19 vaccines. JAMA. 2023;329(1):19–20. doi: 10.1001/jama.2022.22759
   PubMed Web of Science ®Google Scholar
• Grange ZL, Goldstein T, Johnson CK, et al. Ranking the risk of animal-to-human spillover for newly discovered viruses. Proc Natl Acad Sci U S A. 2021;118(15):e2002324118. doi: 10.1073/pnas.2002324118
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2022h. WHO consultation on COVID vaccines research: why do we need a pan-sarbecovirus vaccine? [accessed 2023 Sep 4]. Available from: https://www.who.int/news-room/events/detail/2022/01/28/default-calendar/who-consultation-on-covid-vaccines-research-why-do-we-need-a-pan-sarbecovirus-vaccine.
   Google Scholar
• Coléon S, Wiedemann A, Surénaud M, et al. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. EBioMedicine. 2022;80:104062. doi: 10.1016/j.ebiom.2022.104062
   PubMed Web of Science ®Google Scholar
• Liu Z, Chan JFW, Zhou J, et al. A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 omicron variant. Cell Res. 2022;32(5):495–497. doi: 10.1038/s41422-022-00631-z
   PubMed Web of Science ®Google Scholar
• Tan CW, Chia WN, Young BE, et al. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N Engl J Med. 2021;385:1401–1406. doi: 10.1056/NEJMoa2108453
   PubMed Web of Science ®Google Scholar
• Lui Z, Zhou J, Lu L. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. PNAS. 2023;120(11):e2221713120. doi: 10.1073/pnas.2221713120
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397(10269):99–111. doi: 10.1016/S0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2023e. Development and licensure of vaccines to prevent COVID-19 [accessed 2023 Nov 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19.
   Google Scholar
• Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28(3–4):117–129. doi: 10.1038/s41434-020-00204-y
   PubMed Web of Science ®Google Scholar
• Pollock KM, Cheeseman HM, Szubert AJ, et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine. 2022;44:101262. doi: 10.1016/j.eclinm.2021.101262
   PubMedGoogle Scholar
• Szubert AJ, Pollock KM, Cheeseman HM, et al. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. EClinicalMedicine. 2023;56:101823. doi: 10.1016/j.eclinm.2022.101823
   PubMedGoogle Scholar